Horizon Pharma licenses Latin American rights to Duexis to Grunenthal

Horizon Pharma has exclusively licensed Duexis (ibuprofen and famotidine) to Grunenthal for commercialisation in Latin America. Duexis is a single-tablet combination of the NSAID ibuprofen and the histamine H2-receptor antagonist famotidine. It is indicated in the US for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers, in patients who are taking ibuprofen. The FDA approved Duexis in April 2011.